Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted <scp>EPOCH</scp>‐R
Lisa Giulino‐Roth(Cornell University), John P. Leonard(New York University), Amanda Termuhlen, Jakub Svoboda(UPMC Hillman Cancer Center), Sonali M. Smith(University of Chicago), Catherine M. Bollard(Children's National), J Sima(SUNY Upstate Medical University), James Godfrey(City of Hope), Christopher J. Forlenza(Memorial Sloan Kettering Cancer Center), Melinda Pauly(Emory University), Matthew J. Barth(Roswell Park Comprehensive Cancer Center), Deborah M. Stephens(University of North Carolina at Chapel Hill), Sarah Alexander(BC Children's Hospital), Benjamin Mizukawa(Cincinnati Children's Hospital Medical Center), William Zeitler(University of Iowa Hospitals and Clinics), Tara J. O’Donohue, Matthew J. Oberley(Caris Life Sciences (United States)), Kristie A. Blum(Emory University), Carla Casulo(University of Rochester Medical Center), Nancy L. Bartlett(Washington University in St. Louis), Zeinab Afify(Primary Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), William Martin‐Doyle(Brigham and Women's Hospital), Ann S. LaCasce(Otsuka (Japan)), Hema Dave(Children's National), Zhengming Chen(Cornell University), Michael E. Williams(University of Virginia), Beth Christian(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Sheila Weitzman(Hospital for Sick Children), Burton Appel(Hackensack University Medical Center), Kimberly Davies(Boston Children's Hospital), Jennifer Levine(Cornell University)
Cited by 129
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k